➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Baxter
McKinsey
McKesson

Last Updated: June 18, 2021

DrugPatentWatch Database Preview

VESICARE LS Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Vesicare Ls, and what generic alternatives are available?

Vesicare Ls is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-four patent family members in twenty-two countries.

The generic ingredient in VESICARE LS is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

Summary for VESICARE LS
Drug patent expirations by year for VESICARE LS
Drug Prices for VESICARE LS

See drug prices for VESICARE LS

Recent Clinical Trials for VESICARE LS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Hospitalier Universitaire VaudoisPhase 4
Brigitte SchürchPhase 4
The Methodist Hospital SystemPhase 4

See all VESICARE LS clinical trials

Pharmacology for VESICARE LS

US Patents and Regulatory Information for VESICARE LS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VESICARE LS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0801067 C00801067/01 Switzerland   Try Before You Buy PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
0801067 04C0032 France   Try Before You Buy PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067 SPC/GB04/029 United Kingdom   Try Before You Buy PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Harvard Business School
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.